Posted by Michael Wonder on 23 Jun 2024
Lexicon Pharmaceuticals resubmits sotagliflozin NDA for type 1 diabetes
21 June 2024 - Lexicon seeks approval for sotagliflozin as an adjunct to insulin therapy for glycemic control in people with type 1 diabetes and chronic kidney disease.
Lexicon Pharmaceuticals today announced that, following multiple interactions with and recent feedback from the US FDA, it has resubmitted its new drug application for sotagliflozin as an adjunct to insulin therapy for glycemic control in people with type 1 diabetes and chronic kidney disease.
